ICS 2005 Scientific Podium Poster Session S15 - Clinical Pharmacology:Chaired by Martin Michel and Lynn Stothers

	Friday 2nd September 2005
	14:00 - 15:00

14:00

#109 Safety and efficacy of amitriptyline for the treatment of Interstitial Cystitis: Results of a placebo controlled trial and a prospective long term observational study.

van Ophoven A1, Hertle L1 1. Dept. of Urology, University Hospital

14:07

#110 Lower Sample Size Requirements for Clinical Trials Studying Diary Symptoms in OAB Patients: Use of the Overactive Bladder Symptom Composite Score for Sample Size Determination in Clinical Trials

Harnett M1, Sandage B1, Schwiderski U1, Sabounjian L1, Harnett K1 1. Indevus Pharmaceuticals, Inc.

14:15

#111 Improvements in bladder condition in OAB as perceived and experienced by patients in a solifenacin vs.tolterodine multinational trial (STAR study)

Chapple C1, Ballanger P2, Hatzichristou D3, Liehne J4, van Erps P5, van de Weijer P6, Drogendijk T7, Wright M7, Bolodeoku J7 1. Royal Hallamshire Hospital, UK, 2. Hôpital Pellegrin Tondu, France, 3. Papageorgiou GH, Greece, 4. Ústecke Urocentrum, Czech Republic, 5. AZ Middelheim, Belgium, 6. Gelre Ziekenhuizen, Netherlands;, 7. Yamanouchi

14:22

#112 A DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMISED, MULTIPLE ORAL DOSE, DOSE ESCALATION TRIAL INVESTIGATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SVT-40776 IN HEALTHY POSTMENOPAUSAL WOMEN

Rigau D1, Lagunas C1, Sanagustin J1, Alavarez D1, Viayna C1, López R1, Fernández A1 1. Laboratorios SALVAT, S.A.

14:30

#113 THE EFFECTIVE COMBINATION OF TWO ANTICHOLINERGIC DRUGS WITHOUT AN INCREASE OF SIDE EFFECTS IN PATIENTS WITH NEUROGENIC BLADDER

Schäfer T1, Horstmann M1, Aguilar Y1, Kuczyk M1, Stenzl A1, Sievert K1 1. Department of Urology

14:37

#114 A pharmacodynamic study in children with primary nocturnal enuresis using a new ‘melt’ orodispersible formulation of desmopressin

Bogaert G1, Vande Walle J2, Mattson S3, Schurmans T4, Hoebeke P2, Deboe V5, Norgaard J6 1. UZ Gasthuisberg, 2. Universitaire Ziekenhuis Gent, 3. University of Linkoping, 4. Hôpital Universitaire Des Enfants Reine Fabiola, 5. Vrije Universiteit, 6. Ferring Pharmaceuticals A/S

14:45

#115 Comparison of Persistence Among Therapies for Overactive Bladder: A Retrospective Pharmacy Claims Analysis

Cisternas M1, Noe L1, Patel B2, Remigio-Baker R2, Williamson T3, Black L4 1. Ovation Research Group, 2. MedImpact Healthcare Systems, Inc. , 3. Yamanouchi Pharma America, 4. GlaxoSmithKline

14:52

#116 The Effect Of Duloxetine Dose Escalation and Tapering on the Incidence of Adverse Events (AE) in Women with Stress Urinary Incontinence (SUI)

Bump R1, Yalcin I1, Voss S 1 1. Lilly Research Laboratories

Content Visitors (staff only)

Clinical Pharmacology:Chaired by Martin Michel and Lynn Stothers

Scientific Podium Poster Session S15

Session Schedule

Comments

Chat